Evommune (EVMN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for June 2, 2026, to be held virtually.
Shareholders are invited to vote on key proposals, including director elections and auditor ratification.
Voting matters and shareholder proposals
Election of two Class I director nominees, Luis Peña and Eugene A. Bauer, to serve until the 2029 Annual Meeting.
Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxies may vote on other business that arises during the meeting or any adjournments.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Evommune
- Advancing novel oral and biologic therapies for inflammation with strong clinical and financial momentum.EVMN
Corporate presentation8 May 2026 - Net loss widened to $21.7 million in Q1 2026, with cash runway extended through 2028.EVMN
Q1 20268 May 2026 - Shareholders will vote on director elections and auditor ratification, with strong governance and ESG oversight.EVMN
Proxy filing21 Apr 2026 - Biotech enables resale of 4.5M shares post-IPO, advancing inflammation therapies amid sector risks.EVMN
Registration filing17 Apr 2026 - EVO756 phase IIb trial targets migraine prevention with a novel oral MRGPRX2 antagonist.EVMN
Status update13 Apr 2026 - EVO301 showed rapid, significant efficacy and safety in phase 2A atopic dermatitis, enabling phase 2B plans.EVMN
Study result12 Apr 2026 - Advancing novel oral and biologic therapies for inflammation with key data expected in 2026.EVMN
Corporate presentation7 Apr 2026 - Strong clinical progress and $125M financing extend cash runway through 2028.EVMN
Q4 20256 Mar 2026 - Advancing two Phase 2 programs for chronic inflammation with key data readouts in 2026.EVMN
Corporate presentation10 Feb 2026